221 related articles for article (PubMed ID: 33109741)
1. Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting.
Morris JS; Luthra R; Liu Y; Duose DY; Lee W; Reddy NG; Windham J; Chen H; Tong Z; Zhang B; Wei W; Ganiraju M; Broom BM; Alvarez HA; Mejia A; Veeranki O; Routbort MJ; Morris VK; Overman MJ; Menter D; Katkhuda R; Wistuba II; Davis JS; Kopetz S; Maru DM
Clin Cancer Res; 2021 Jan; 27(1):120-130. PubMed ID: 33109741
[TBL] [Abstract][Full Text] [Related]
2. A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues.
de Back TR; Wu T; Schafrat PJ; Ten Hoorn S; Tan M; He L; van Hooff SR; Koster J; Nijman LE; Vink GR; Beumer IJ; Elbers CC; Lenos KJ; Sommeijer DW; Wang X; Vermeulen L
Life Sci Alliance; 2024 Aug; 7(8):. PubMed ID: 38782602
[TBL] [Abstract][Full Text] [Related]
3. A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer.
Piskol R; Huw L; Sergin I; Kljin C; Modrusan Z; Kim D; Kljavin N; Tam R; Patel R; Burton J; Penuel E; Qu X; Koeppen H; Sumiyoshi T; de Sauvage F; Lackner MR; de Sousa E Melo F; Kabbarah O
Clin Cancer Res; 2019 Jul; 25(14):4431-4442. PubMed ID: 31004000
[TBL] [Abstract][Full Text] [Related]
4. Robust transcriptional tumor signatures applicable to both formalin-fixed paraffin-embedded and fresh-frozen samples.
Chen R; Guan Q; Cheng J; He J; Liu H; Cai H; Hong G; Zhang J; Li N; Ao L; Guo Z
Oncotarget; 2017 Jan; 8(4):6652-6662. PubMed ID: 28036264
[TBL] [Abstract][Full Text] [Related]
5. Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes.
Ragulan C; Eason K; Fontana E; Nyamundanda G; Tarazona N; Patil Y; Poudel P; Lawlor RT; Del Rio M; Koo SL; Tan WS; Sclafani F; Begum R; Teixeira Mendes LS; Martineau P; Scarpa A; Cervantes A; Tan IB; Cunningham D; Sadanandam A
Sci Rep; 2019 May; 9(1):7665. PubMed ID: 31113981
[TBL] [Abstract][Full Text] [Related]
6. 72-gene classifier for predicting prognosis of estrogen receptor-positive and node-negative breast cancer patients using formalin-fixed, paraffin-embedded tumor tissues.
Nishio M; Naoi Y; Tsunashima R; Nakauchi C; Kagara N; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
Clin Breast Cancer; 2014 Jun; 14(3):e73-80. PubMed ID: 24461457
[TBL] [Abstract][Full Text] [Related]
7. A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry.
Li X; Larsson P; Ljuslinder I; Ling A; Löfgren-Burström A; Zingmark C; Edin S; Palmqvist R
Pathol Res Pract; 2021 Apr; 220():153379. PubMed ID: 33721619
[TBL] [Abstract][Full Text] [Related]
8. Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer.
Omolo B; Yang M; Lo FY; Schell MJ; Austin S; Howard K; Madan A; Yeatman TJ
BMC Med Genomics; 2016 Oct; 9(1):65. PubMed ID: 27756306
[TBL] [Abstract][Full Text] [Related]
9. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.
Sveen A; Bruun J; Eide PW; Eilertsen IA; Ramirez L; Murumägi A; Arjama M; Danielsen SA; Kryeziu K; Elez E; Tabernero J; Guinney J; Palmer HG; Nesbakken A; Kallioniemi O; Dienstmann R; Lothe RA
Clin Cancer Res; 2018 Feb; 24(4):794-806. PubMed ID: 29242316
[No Abstract] [Full Text] [Related]
10. Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry.
Trinh A; Trumpi K; De Sousa E Melo F; Wang X; de Jong JH; Fessler E; Kuppen PJ; Reimers MS; Swets M; Koopman M; Nagtegaal ID; Jansen M; Hooijer GK; Offerhaus GJ; Kranenburg O; Punt CJ; Medema JP; Markowetz F; Vermeulen L
Clin Cancer Res; 2017 Jan; 23(2):387-398. PubMed ID: 27459899
[TBL] [Abstract][Full Text] [Related]
11. A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer.
Low YS; Blöcker C; McPherson JR; Tang SA; Cheng YY; Wong JYS; Chua C; Lim TKH; Tang CL; Chew MH; Tan P; Tan IB; Rozen SG; Cheah PY
Cancer Lett; 2017 Sep; 403():13-20. PubMed ID: 28624625
[TBL] [Abstract][Full Text] [Related]
12. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.
Manceau G; Imbeaud S; Thiébaut R; Liébaert F; Fontaine K; Rousseau F; Génin B; Le Corre D; Didelot A; Vincent M; Bachet JB; Chibaudel B; Bouché O; Landi B; Bibeau F; Leroy K; Penault-Llorca F; Van Laethem JL; Demetter P; Tejpar S; Rossi S; Mosakhani N; Osterlund P; Ristamäki R; Sarhadi V; Knuutila S; Boige V; André T; Laurent-Puig P
Clin Cancer Res; 2014 Jun; 20(12):3338-47. PubMed ID: 24771647
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
[No Abstract] [Full Text] [Related]
14. Consensus molecular subtype classification of colorectal adenomas.
Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
[TBL] [Abstract][Full Text] [Related]
15. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
[TBL] [Abstract][Full Text] [Related]
16. CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models.
Eide PW; Bruun J; Lothe RA; Sveen A
Sci Rep; 2017 Nov; 7(1):16618. PubMed ID: 29192179
[TBL] [Abstract][Full Text] [Related]
17. CINSARC signature outperforms gold-standard TNM staging and consensus molecular subtypes for clinical outcome in stage II-III colorectal carcinoma.
Brunac AC; Fourquet J; Perot G; Jaffrelot M; Meilleroux J; Danjoux M; Filleron T; Nicolaï V; Guimbaud R; Icher S; Farés N; Selves J; Chibon F
Mod Pathol; 2022 Dec; 35(12):2002-2010. PubMed ID: 36202996
[TBL] [Abstract][Full Text] [Related]
18. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
19. Identification and Clinical Validation of a Novel 4 Gene-Signature with Prognostic Utility in Colorectal Cancer.
Ahluwalia P; Mondal AK; Bloomer C; Fulzele S; Jones K; Ananth S; Gahlay GK; Heneidi S; Rojiani AM; Kota V; Kolhe R
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387239
[TBL] [Abstract][Full Text] [Related]
20. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]